VitaSpring Biomedical Co. Ltd.
VSBC · OTC
1/31/2023 | 1/31/2022 | 1/31/2021 | 1/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.72 | -9.93 | 2.02 | -22.91 |
| FCF Yield | -0.00% | 0.00% | -0.00% | -0.00% |
| EV / EBITDA | -780.57 | 1,933.29 | -2,576.33 | -1,202.68 |
| Quality | ||||
| ROIC | 195.57% | 61.74% | -109.98% | 0.00% |
| Gross Margin | 0.00% | 36.84% | 45.21% | 11.20% |
| Cash Conversion Ratio | 0.02 | 0.07 | 0.10 | -0.02 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 618.39% | 143.55% | -2.29% |
| Free Cash Flow Growth | -756.51% | 128.04% | -40,023.81% | 99.69% |
| Safety | ||||
| Net Debt / EBITDA | -0.06 | 0.24 | 0.11 | 0.00 |
| Interest Coverage | 0.00 | 627.59 | -634.90 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -4,012.20 | 63.11 | 0.00 | 0.00 |